Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

Daruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, Chris J. Bowden, Paul J.E. Miller, Rachel Elizabeth Swart, Mark S. Walker, Paul Haluska, Pamela N. Munster, John Marshall, Omid Hamid, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Fingerprint Dive into the research topics of 'Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds